SCHEMBL11900901

SCHEMBL11900901

COC1CC(n2c([C@H](C)NC(=O)OC(C)(C)C)nc3ccc(F)cc32)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.40
PIK3R1 P27986 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
BRD4 O60885 1/20 0.40
CYP11B2 P19099 5/20 0.39
IDO1 P14902 3/20 0.38
KCNH2 Q12809 1/20 0.38
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
OGFRL1 Q5TC84 1/20 0.36
CYP11B1 P15538 3/20 0.36
ADRB1 P08588 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP19A1 P11511 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11901639 1.00 PIK3CD (0.40) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11900899 1.00 PIK3CD (0.40) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL2507652 0.89 PIK3CD (0.49) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL2507650 0.89 PIK3CD (0.49) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11901298 0.88 PIK3CD (0.46) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11902050 0.87 PIK3CD (0.45) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11964466 0.87 PIK3CD (0.45) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11902027 0.86 BACE1 (0.41) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11901971 0.86 BACE1 (0.41) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG
SCHEMBL11901969 0.86 BACE1 (0.41) PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 PIK3CD 2/4885PIK3R1 20/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.